Pulmonary Drug Delivery Devices Market (Product Type - Dry Powder Inhalers, Metered Dose Inhalers and Nebulizers; Application - Asthma, COPD, and Cystic Fibrosis; Distribution Channel - Retail Pharmacies, Hospital Pharmacies, and E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2030

Description

Global Pulmonary Drug Delivery Systems Market: Snapshot

Pulmonary drug delivery systems refer to the technologies that are used to treat diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis using pulmonary route of drug administration. While these systems have been in medical use for more than six decades, recent technological advancements in pulmonary drug delivery systems have expanded their potential application in other diseases as well including diabetes, lung cancer, and others. The market for pulmonary drug delivery systems is projected to be worth US$28.7 bn by the end of 2019, propagating at a notable CAGR of 4.4% during the forecast period of 2017 to 2019.

Apart from growing adoption of pulmonary drug delivery as an alternative to route of drug delivery, the market is gaining traction from some of the other factors such as the development of smart and digital inhalers, increasing number of smokers, and growth of the distribution network since the emergence of ecommerce. On the flip side, regulatory hurdles, patent expiration of some of the blockbuster drugs, and issues pertaining to the stability of drugs are some of the restraints hindering the prosperity of the global pulmonary drug delivery systems market. However, the vendors of this market are expected to gain vast new opportunities in the emerging economies of Asia Pacific.

Metered Dore Inhalers Market’s Key Product Segment

On the basis of product type, the pulmonary drug delivery devices market has been segmented into nebulizers, metered dose inhalers (MDI), and dry powder inhaler (DPI). As of 2017, the MDI segment has the maximum demand, providing for a revenue of US$14,512.7 mn. MDIs can be further classified into three categories based on the drugs delivered, namely metered dose inhalers with bronchodilators, corticosteroids, and a combination of both. However, patents of blockbuster drugs such as Advair HFA/Seretide Evohaler and Ventolin HFA/Ventolin Evohaler by GlaxoSmithKline have expired in 2017 and is expected to reflect negatively over the MDI segment. On the other hand, the demand for nebulizers and DPIs have been anticipated multiply profitably during the forecast period of 2017 to 2019.

The report also classifies the pulmonary drug delivery systems market on the basis of application, into COPD, cystic fibrosis, and asthama. The latter provided for a demand worth of US$16,085.9 mn in 2017 and is projected to remain most profitable over the course of next seven years. The analysts of the report have also bifurcated the market on the basis of distribution channel into hospital pharmacies, retail pharmacies, and ecommerce.

Developed and Developing Economies Driving Demand

In terms of region, North America, Europe, and Asia Pacific are the three regions of greatest potential. According to the analysts, the North America pulmonary drug delivery systems market was worth US$10,072.8 mn, gaining traction from factors such as strong prevalence of asthma, consistent focus of the government to reduce treatment costs, and escalating percentage of geriatrics in the U.S. The European market for pulmonary drug delivery systems, which was valued at US$7,059.0 mn in 2017, is driven by the countries of Germany, France, the U.K., Italy, and Spain. Some of the major factors responsible for this stunted growth in Europe include active penetration by generic makers and government austerity measures in key countries to reduce prices. Vastly populated region of Asia Pacific, driven by the emerging economies of China and India, is expected to generate demand for pulmonary drug delivery devices at a robust rate during the forecast period of this report.

AstraZeneca Plc, Novartis AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Merck & Co. Inc., and Teva Pharmaceutical Industries Ltd. are a few key players operating in the global pulmonary drug delivery systems market.

TABLE OF CONTENT

1.Preface
    1.1.Report Scope
    1.2.Market Segmentation 
    1.3.Research Highlights

2.Assumptions and Research Methodology
    2.1.Assumptions
    2.2.Research Methodology

3.Executive Summary

4.Market Overview
    4.1.Product Type Overview
    4.2.Key Industry Events
    4.3.Market Opportunity Map

5.Market Dynamics
    5.1.Drivers and Restraints Snapshot Analysis
    5.2.Drivers
    5.3.Restraints
    5.4.Opportunity Analysis
    5.5.Opportunities
    5.6.Trends
    5.7.Porter’s Five Forces Analysis
    5.8.Value Chain Snapshot

6.Pulmonary Drugs Market Analysis, by Product Type
    6.1.Key Findings
    6.2.Introduction
    6.3.Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product Type
    6.4.Global Pulmonary Drug Delivery Devices Market Forecast, by Product Type
          6.4.1.Global Dry Powder Inhalers (DPIs) Market Revenue (US$ Mn) and Volume (million units), 2014–2024
          6.4.2.Global Metered Dose Inhalers (MDIs) Market Revenue (US$ Mn) and Volume (million units), 2014–2024
          6.4.3.Global Nebulizers Market Revenue (US$ Mn) and Volume (million units), 2014–2024
    6.5.Global Pulmonary Drugs Market Attractiveness Analysis, by Product Type
    6.6.Key Trends

7.Pulmonary Drug Delivery Devices Market Analysis, by Application
    7.1.Key Findings
    7.2.Introduction
    7.3.Global Pulmonary Drug Delivery Devices Market Value Share Analysis, By Application, 2016 and 2024
    7.4.Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and volume (million units) Forecast, By Application, 2014–2024
          7.4.1.Global Asthma Market Revenue (US$ Mn) and volume (million units), 2014–2024
          7.4.2.Global COPD Market Revenue (US$ Mn) and volume (million units), 2014–2024
          7.4.3.Global Cystic Fibrosis Market Revenue (US$ Mn) and volume (million units), 2014–2024
          7.4.4.Global Other Applications Market Revenue (US$ Mn) and volume (million units), 2014–2024
          7.4.5.Global Pulmonary Drug Delivery Devices Market Attractiveness By Application
    7.5.Key Trends

8.Pulmonary Drug Delivery Devices Market Analysis, by Distribution Channel
    8.1.Key Findings
    8.2.Introduction
    8.3.Global Pulmonary Drug Delivery Devices Market Value Share Analysis, By Distribution Channel, 2016 and 2024
    8.4.Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, By Distribution Channel, 2015–2024
          8.4.1.Global Retail Pharmacies Market Revenue (US$ Mn) and Volume (million units), 2014–2024
          8.4.2.Global Hospital Pharmacies Market Revenue (US$ Mn) and Volume (million units), 2014–2024
          8.4.3.Global E-commerce Market Revenue (US$ Mn) and Volume (million units), 2014–2024
    8.5.Global Pulmonary Drug Delivery Devices Market Attractiveness by Distribution Channel

9.Pulmonary Drug Delivery Devices Market Analysis, By Region
    9.1.Global Scenario
    9.2.Global Pulmonary Drug Delivery Devices Market Value Share Analysis By Region, 2016 and 2024
    9.3.Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, By Region, 2016–2024
    9.4.Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Region

10.North America Pulmonary Drug Delivery Devices Market Analysis
    10.1.Key Findings
    10.2.North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, 2016–2024
    10.3. North America Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2015–2024
    10.4.North America Market Attractiveness Analysis, by Country
    10.5.North America Market Value Share Analysis, by Product Type, 2016 and 2024
    10.6.North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Product Type, 2016–2024
    10.7.North America Market Value Share Analysis, by Application, 2016 and 2024
    10.8.North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Application, 2016–2024
    10.9.North America Market Revenue Share Analysis, by Distribution Channel, 2016 and 2024
    10.10.North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Distribution Channel, 2016–2024
    10.11.North America Market Value Share Analysis, by Country, 2016 and 2024
    10.12.North America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Country, 2016–2024
    10.13.North America Market Attractiveness Analysis, by Product Type
    10.14.North America Market Attractiveness Analysis, by Application
    10.15.North America Market Attractiveness Analysis, by Distribution Channel

11.Europe Pulmonary Drug Delivery Devices Market Analysis
    11.1.Key Findings
    11.2.Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, 2016–2024
    11.3. Europe Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2015–2024
    11.4.Europe Market Attractiveness Analysis, by Country
    11.5.Europe Market Value Share Analysis, by Product Type, 2016 and 2024
    11.6.Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Product Type, 2016–2024
    11.7.Europe Market Value Share Analysis, by Application, 2016 and 2024
    11.8.Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Application, 2016–2024
    11.9.Europe Market Revenue Share Analysis, by Distribution Channel, 2016 and 2024
    11.10.Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Distribution Channel, 2016–2024
    11.11.Europe Market Value Share Analysis, by Country, 2016 and 2024
    11.12.Europe Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Country, 2016–2024
    11.13.Europe Market Attractiveness Analysis, by Product Type
    11.14.Europe Market Attractiveness Analysis, by Application
    11.15.Europe Market Attractiveness Analysis, by Distribution Channel

12.Asia Pacific Pulmonary Drug Delivery Devices Market Analysis
    12.1.Key Findings
    12.2.Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, 2016–2024
    12.3. Asia Pacific Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2015–2024
    12.4.Asia Pacific Market Attractiveness Analysis, by Country
    12.5.Asia Pacific Market Value Share Analysis, by Product Type, 2016 and 2024
    12.6.Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Product Type, 2016–2024
    12.7.Asia Pacific Market Value Share Analysis, by Application, 2016 and 2024
    12.8.Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Application, 2016–2024
    12.9.Asia Pacific Market Revenue Share Analysis, by Distribution Channel, 2016 and 2024
    12.10.Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Distribution Channel, 2016–2024
    12.11.Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
    12.12.Asia Pacific Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Country, 2016–2024
    12.13.Asia Pacific Market Attractiveness Analysis, by Product Type
    12.14.Asia Pacific Market Attractiveness Analysis, by Application
    12.15.Asia Pacific Market Attractiveness Analysis, by Distribution Channel

13.Latin America Pulmonary Drug Delivery Devices Market Analysis
    13.1.Key Findings
    13.2.Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, 2016–2024
    13.3. Latin America Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2015–2024
    13.4.Latin America Market Attractiveness Analysis, by Country
    13.5.Latin America Market Value Share Analysis, by Product Type, 2016 and 2024
    13.6.Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Product Type, 2016–2024
    13.7.Latin America Market Value Share Analysis, by Application, 2016 and 2024
    13.8.Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Application, 2016–2024
    13.9.Latin America Market Revenue Share Analysis, by Distribution Channel, 2016 and 2024
    13.10.Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Distribution Channel, 2016–2024
    13.11.Latin America Market Value Share Analysis, by Country, 2016 and 2024
    13.12.Latin America Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Country, 2016–2024
    13.13.Latin America Market Attractiveness Analysis, by Product Type
    13.14.Latin America Market Attractiveness Analysis, by Application
    13.15.Latin America Market Attractiveness Analysis, by Distribution Channel

14.Middle East & Africa Pulmonary Drug Delivery Devices Market Analysis
    14.1.Key Findings
    14.2.Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, 2016–2024
    14.3. Middle East & Africa Pulmonary Drug Delivery Devices Market Size and Volume Y-o-Y Growth Projections, 2015–2024
    14.4.Middle East & Africa Market Attractiveness Analysis, by Country
    14.5.Middle East & Africa Market Value Share Analysis, by Product Type, 2016 and 2024
    14.6.Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Product Type, 2016–2024
    14.7.Middle East & Africa Market Value Share Analysis, by Application, 2016 and 2024
    14.8.Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Application, 2016–2024
    14.9.Middle East & Africa Market Revenue Share Analysis, by Distribution Channel, 2016 and 2024
    14.10.Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Distribution Channel, 2016–2024
    14.11.Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
    14.12.Middle East & Africa Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, by Country, 2016–2024
    14.13.Middle East & Africa Market Attractiveness Analysis, by Product Type
    14.14.Middle East & Africa Market Attractiveness Analysis, by Application
    14.15.Middle East & Africa Market Attractiveness Analysis, by Distribution Channel

15.Competition Landscape
    15.1.Global Pulmonary Drugs Market Share Analysis, By Company, (2015)
    15.2.Competitive Dashboard
    15.3.Pipeline Snapshot

16.Company Profiles
    16.1.Boehringer Ingelheim GmbH 
          16.1.1.Company Overview
          16.1.2.Business Overview
          16.1.3.Financial Overview
          16.1.4.SWOT Analysis
          16.1.5.Strategic Overview
    16.2.Novartis AG 
          16.2.1.Company Overview
          16.2.2.Business Overview
          16.2.3.Financial Overview
          16.2.4.SWOT Analysis
          16.2.5.Strategic Overview
    16.3.GlaxoSmithKline plc 
          16.3.1.Company Overview
          16.3.2.Business Overview
          16.3.3.Financial Overview
          16.3.4.SWOT Analysis
          16.3.5.Strategic Overview
    16.4.AstraZeneca plc
          16.4.1.Company Overview
          16.4.2.Business Overview
          16.4.3.Financial Overview
          16.4.4.SWOT Analysis
          16.4.5.Strategic Overview
    16.5.Teva Pharmaceutical Industries Ltd. 
          16.5.1.Company Overview
          16.5.2.Business Overview
          16.5.3.Financial Overview
          16.5.4.SWOT Analysis
          16.5.5.Strategic Overview
    16.6.Merck & Co., Inc. 
          16.6.1.Company Overview
          16.6.2.Business Overview
          16.6.3.Financial Overview
          16.6.4.SWOT Analysis
          16.6.5.Strategic Overview
    16.7.MannKind Corporation 
          16.7.1.Company Overview
          16.7.2.Business Overview
          16.7.3.Financial Overview
          16.7.4.SWOT Analysis
          16.7.5.Strategic Overview
    16.8.F. Hoffmann-La Roche Ltd. 
          16.8.1.Company Overview
          16.8.2.Business Overview
          16.8.3.Financial Overview
          16.8.4.SWOT Analysis
          16.8.5.Strategic Overview
    16.9.Bristol-Myers Squibb Company
          16.9.1.Company Overview
          16.9.2.Business Overview
          16.9.3.Financial Overview
          16.9.4.SWOT Analysis
          16.9.5.Strategic Overview
    16.10.Mylan N.V. 
          16.10.1. Company Overview
          16.10.2. Business Overview
          16.10.3. Financial Overview
          16.10.4. SWOT Analysis
          16.10.5. Strategic Overview
    16.11.Omron Corporation
          16.11.1.Company Overview
          16.11.2.Business Overview
          16.11.3.Financial Overview
          16.11.4.SWOT Analysis
          16.11.5.Strategic Overview
    16.12.3M Healthcare 
          16.12.1.Company Overview
          16.12.2.Business Overview
          16.12.3.Financial Overview
          16.12.4.SWOT Analysis
          16.12.5.Strategic Overview
    16.13.Sunovion Pharmaceuticals, Inc. 
          16.13.1.Company Overview
          16.13.2.Business Overview
          16.13.3.Financial Overview
          16.13.4.SWOT Analysis
          16.13.5.Strategic Overview
    16.14.Koninklijke Philips N.V. 
          16.14.1.Company Overview
          16.14.2.Business Overview
          16.14.3.Financial Overview
          16.14.4.SWOT Analysis
          16.14.5.Strategic Overview
    16.15.Gerresheimer AG 
          16.15.1.Company Overview
          16.15.2.Business Overview
          16.15.3.Financial Overview
          16.15.4.SWOT Analysis
          16.15.5.Strategic Overview
    16.16.Bespak 
          16.16.1.Company Overview
          16.16.2.Business Overview
          16.16.3.Financial Overview
          16.16.4.SWOT Analysis
          16.16.5.Strategic Overview
    16.17.AptarGroup, Inc. 
          16.17.1.Company Overview
          16.17.2.Business Overview
          16.17.3.Financial Overview
          16.17.4.SWOT Analysis
          16.17.5.Strategic Overview
    16.18.SHL Group 
          16.18.1. Company Overview
          16.18.2. Business Overview
          16.18.3. SWOT Analysis
          16.18.4. Strategic Overview
    16.19.Nypro Healthcare Inc. (Jabil Circuit Inc.) 
          16.19.1.Company Overview
          16.19.2.Business Overview
          16.19.3.Financial Overview
          16.19.4.SWOT Analysis
          16.19.5.Strategic Overview
    16.20.Hovione 
          16.20.1.Company Overview
          16.20.2.Business Overview
          16.20.3.Financial Overview
          16.20.4.SWOT Analysis
          16.20.5.Strategic Overview
    16.21.Chiesi Farmaceutici S.p.A. 
          16.21.1.Company Overview
          16.21.2.Business Overview
          16.21.3.Financial Overview
          16.21.4.SWOT Analysis
          16.21.5.Strategic Overview

Choose License Type

Checkout Inquiry Sample